18F-FDG
Diagnostic / imaging agent targets CD38, FAP
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | FLUDEOXYGLUCOSE F18 | — | 2000-06-02 | fda.gov ↗ |
| Approved | US (FDA) | FLUDEOXYGLUCOSE F18 | — | 1994-08-19 | fda.gov ↗ |
Trials 74 · started per year
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT04016818 Background | Jun 2026 → Dec 2027 | breast cancer | Stanford University | Withdrawn | No outcome recorded |
| Phase 0 | NCT06717113 Comparator | Apr → Dec 2025 overdue | plasma cell myeloma | Peking University First Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06740240 Comparator | Mar 2024 → Jun 2026 overdue | neoplasm | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| Phase 0 | NCT02405078 Background | Oct 2015 → Oct 2022 | diffuse large B-cell lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01494012 Background | Apr → Sep 2012 | malignant epithelial tumor of ovary, malignant germ cell tumor of ovary, peritoneum cancer | Stanford University | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05885854 Background | Dec 2021 → Mar 2023 | ischemic disease | Sinotau Pharmaceutical Group | Completed | No outcome recorded |
| Phase 2 | NCT02455453 Background | Apr 2015 → Jan 2019 | breast cancer | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01146054 Background | Oct 2009 → Oct 2013 | malignant pancreatic neoplasm | Stanford University | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01394679 Comparator | May → Dec 2025 overdue | lung cancer | Cell>Point LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06125028 Comparator | May 2024 → Jul 2025 | marginal zone lymphoma | Pentixapharm AG | Terminated | No outcome recorded |
| Phase 3 | NCT02074202 Comparator | Feb 2014 → Mar 2015 | hepatocellular carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05641753 Background | Dec 2022 → Jul 2027 expected | type 1 diabetes mellitus | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 4 | NCT04417998 Comparator | Jun 2020 → Dec 2023 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05322512 Background | May → Dec 2024 | cancer | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| — | NCT05390021 Background | Mar 2024 → Feb 2025 | endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma, endometrial undifferentiated carcinoma, serous adenocarcinoma | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| — | NCT00887718 Background | Aug 2007 → Jun 2011 | Hodgkins lymphoma, non-Hodgkin lymphoma | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 92 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F FDG | “After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG...” NCT03123289 ↗60“The purpose of this study is to determine if the images of the primary lesions of lung cancer and any metastatic lesions seen from the investigational SPECT/CT 99mTC-EC-DG...” NCT01394679 ↗ “Participants with various types of cancer will have PET imaging 50-100 minutes after injection of 68Ga-FAP-CHX and another agent (68Ga-FAPI-04 or 18F-FDG).” NCT05506566 ↗ “PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy” NCT07443696 ↗ “18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.” NCT05515783 ↗ “18F FDG PET/CT imaging may be performed per clinical standard of care.” NCT03181867 ↗ “Initial intravenous injection of 18F-FDG to each subject” NCT05885854 ↗ “The 18F-FDG injection procedure will be injected” NCT01237054 ↗ “Drug: 18F FDG PET/CT scan” NCT03123289 ↗ |
| Known as | 18-fluorodeoxyglucose | “18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for treatment response evaluation” PMID 32909953 ↗ Sep 20201“18-fluorodeoxyglucose (18-FDG), a radioisotope used with positron emission tomography (PET)” NCT01471418 ↗ |
| Known as | 18F-2-fluoro-2-deoxy-D-glucose | “PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)” NCT04831619 ↗ |
| Known as | 18F-Fludeoxyglucose (18F-FDG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00375830 ↗ |
| Known as | 18F-fluorodeoxyglucose | “OBJECTIVE: The goal of this study is to demonstrate the feasibility of simultaneous [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) and magnetic resonance...” PMID 34718774 ↗ Feb 202210“Intravenous bolus administration of 18F-fluorodeoxyglucose (18F-FDG) for total-body PET/CT to measure systemic biodistribution and whole-body glucose metabolism.” NCT07366710 ↗ “subjects are injected with 18F-Fluorodeoxyglucose (18F-FDG), a radioactively labeled glucose molecule which is consumed by macrophages.” NCT03590769 ↗ “18F-Fluorodeoxyglucose (FDG)-PET session to assess the association between FC and glucose metabolism in the human brain.” NCT02193425 ↗ “18F-fluorodeoxyglucose or FDG (to measure whether heart muscle cells are alive)” NCT02003456 ↗ “This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG).” NCT04417998 ↗ “18F-Fluorodeoxyglucose (FDG) injection” NCT00887718 ↗ |
| Known as | 18F-PEG3-FPN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04747561 ↗ |
| Known as | 18FDG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03549598 ↗ |
| Known as | 2-\[18F\]-fluoro-2-deoxy-D-glucose | “2-\[18F\]-fluoro-2-deoxy-D-glucose, called \[18F\]FDG, is a radioactive sugar that is widely used for cancer imaging” NCT02074202 ↗ |
| Known as | 2-deoxy-2-[18F]fluoro-D-glucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03295695 ↗ |
| Known as | 68Ga-FAP-CHX | “68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging.” NCT05515783 ↗1“68Ga-FAP-CHX is promising as an excellent imaging agent applicable to various cancers” NCT05506566 ↗ |
| Known as | 68Ga-NB381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385652 ↗ |
| Known as | [18F]-Fluorodeoxyglucose ([18F]-FDG) | “[18F]-Fluorodeoxyglucose ([18F]-FDG)” NCT02599194 ↗ |
| Known as | [18F]Fluoro-2-deoxy-2-D-glucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01917136 ↗ |
| Known as | [18F]fluoro-2-deoxy-D-glucose (FDG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02317783 ↗ |
| Known as | FDG | “OBJECTIVE: The goal of this study is to demonstrate the feasibility of simultaneous [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) and magnetic resonance...” PMID 34718774 ↗ Feb 20226“subjects are injected with 18F-Fluorodeoxyglucose (18F-FDG), a radioactively labeled glucose molecule which is consumed by macrophages.” NCT03590769 ↗ “18F-fluorodeoxyglucose or FDG (to measure whether heart muscle cells are alive)” NCT02003456 ↗ “[18F]-Fluorodeoxyglucose (FDG) PET/ MRI” NCT04273555 ↗ “18F-Fluorodeoxyglucose (FDG) injection” NCT00887718 ↗ “2-deoxy-2-[18F]fluoro-D-glucose (FDG)” NCT03295695 ↗ |
| Known as | Fludeoxyglucose (18F) (FDG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01146054 ↗ |
| Known as | Fludeoxyglucose 18F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03937583 ↗ |
| Known as | Fludeoxyglucose F-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02149173 ↗ |
| Known as | Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02379377 ↗ |
| Known as | fluorodeoxyglucose | “with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions” NCT03891914 ↗1“[18F]-Fluorodeoxyglucose (FDG) PET/ MRI” NCT04273555 ↗ |
| Known as | Fluorodeoxyglucose F18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06630845 ↗ |
| Known as | NB381 | “ultimately producing the CD38-targeted nuclear medicine small molecule diagnostic and therapeutic agent-68Ga-labeled nanobody NB381.” NCT06385652 ↗ |
| Modality | Diagnostic / imaging agent | “FDG PET scan of body” NCT00001849 ↗ |
| Route | Intravenous | “will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG” NCT00816335 ↗ |
| Target | FAP | “As an emerging molecule targeting FAP” NCT05506566 ↗ |